This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting
by Zacks Equity Research
AbbVie's (ABBV) key cancer drug, Imbruvica, in combination with Gazyva, gets FDA approval for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in first-line setting.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $128.99, marking a +0.59% move from the previous day.
Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
Top Research Reports for Johnson & Johnson, Boeing & Starbucks
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Boeing (BA) and Starbucks (SBUX).
Friday Rally Helps the Markets Recover Earlier Weekly Losses
by David Borun
Positive earnings data and an end to the government shutdown help keep the 2019 rally gooing
AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down
by Zacks Equity Research
AbbVie (ABBV) misses estimates for both earnings and revenues in fourth quarter. Biosimilar competition impacts Humira sales in ex-U.S. markets. Imbruvica and Mavyret offset Humira decline.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV
by Zacks Equity Research
J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Dow 30 Stock Roundup: UTX, TRV, PG, JNJ Earnings Impress, IBM Revenues Decline Y/Y
by Swarup Gupta
The index traversed an eventful, yet holiday-shortened week.
Alphabet ECG Feature OK'd by FDA, Healthcare Plans on Track
by Zacks Equity Research
Alphabet's (GOOGL) Verily scores FDA clearance for its electrocardiogram technology (ECG) in its Study Watch.
JNJ Beats, Offers Bleak Outlook: Health Care ETFs in Focus
by Sweta Killa
Johnson & Johnson expects its sales growth to slow down this year due to pricing pressures and generic-drug competition for its pharmaceutical division. This has put healthcare ETFs in focus.
Company News For Jan 23, 2019
by Zacks Equity Research
Companies In The News Are: JNJ,SWK,ARNC,BG
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.
China's Weak Economic Data and News from EBay, IBM, Halliburton, & More
by Ryan McQueeney
Ryan McQueeney recaps China's latest economic data as well as earnings results from Johnson & Johnson and Halliburton. He also highlights activist interest in EBay. Later, Ryan chats with Dave Bartosiak about today's news and the upcoming report of IBM.
Market Fears Chinese Economic Slowdown
by Zacks Equity Research
Market Fears Chinese Economic Slowdown
China Trade Reckoning Back in Focus, Plus Q4 Reports: JNJ, TRV, HAL
by Mark Vickery
China???s 6.6% annual growth was its lowest in nearly 30 years, and Xi has called a private meeting of party heads to discuss a way forward.
J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.
J&J (JNJ) Beats Estimates for Earnings & Sales in Q4
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018. 2019 sales view misses expectations. Shares up in pre-market trading
AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study
by Zacks Equity Research
AbbVie's (ABBV) Imbruvica falls short of meeting the primary endpoint of PFS or OS benefit in a phase III study that probed its combo usage in first-line metastatic pancreatic cancer.
Q4 2018 Earnings Reports in Focus
by Zacks Equity Research
Q4 2018 Earnings Reports in Focus
After MLK Day Today, Markets Go for 5 Straight Up Weeks
by Mark Vickery
In observance of Dr. Martin Luther King, Jr's birthday, markets are closed today.
The Zacks Analyst Blog Highlights: Apple, Johnson & Johnson, Amazon and Alphabet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Johnson & Johnson, Amazon and Alphabet
Third Straight Week of Gains to Start 2019
by David Borun
Positive sentiment erases 2018's losses.
Apple Expands in Healthcare, Partners Johnson & Johnson
by Zacks Equity Research
Apple (AAPL) partners with Johnson & Johnson to conduct multi-year research study for early detection of irregular heart conditions.
Key Takeaways from Q4 Earnings Results Thus Far
by Sheraz Mian
First, growth is decelerating. This isn't a surprise, as we knew already that Q4 growth would be materially below the pace set in the first three quarters of the year.